TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair

Alan DAL PRA; Emilie LALONDE; Theodorus VAN DER KWAST; Andrew EVANS; Michael MILOSEVIC; Fred SAAD; Colin COLLINS; Jeremy SQUIRE; Wan LAM; Tarek A BISMAR; Paul C BOUTROS; Robert G BRISTOW; Jenna SYKES; Fiona WARDE; Adrian ISHKANIAN; Alice MENG; Chad MALOFF; John SRIGLEY; Anthony M JOSHUA; Gyorgy PETROVICS

doi:10.1158/1078-0432.CCR-13-1049

Back

TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair

Journal article

Open access

Peer reviewed

TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair

Alan DAL PRA, Emilie LALONDE, Theodorus VAN DER KWAST, Andrew EVANS, Michael MILOSEVIC, Fred SAAD, Colin COLLINS, Jeremy SQUIRE, Wan LAM, Tarek A BISMAR, …

Clinical cancer research, Vol.19(18), pp.5202-5209

2013

DOI: https://doi.org/10.1158/1078-0432.CCR-13-1049

PMID: 23918607

Abstract

Tumors of the urinary system

Urinary tract. Prostate gland

Gynecology. Andrology. Obstetrics

Pharmacology. Drug treatments

Nephrology. Urinary tract diseases

Biological and medical sciences

Multiple tumors. Solid tumors. Tumors in childhood (general aspects)

Medical sciences

Antineoplastic agents

Male genital diseases

Tumors

Files and links (1)

url

https://doi.org/10.1158/1078-0432.CCR-13-1049View

Published (Version of record) Open

Metrics

7 Record Views

37 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.147 Prostate Cancer; 1.147.859 Androgen Receptor
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
Creators: Alan DAL PRA - Departments of Radiation Oncology, Medical Biophysics, Medical Oncology, Laboratory Medicine and Pathology and Biostatistics, University of Toronto, Canada
Emilie LALONDE - Departments of Radiation Oncology, Medical Biophysics, Medical Oncology, Laboratory Medicine and Pathology and Biostatistics, University of Toronto, Canada
Theodorus VAN DER KWAST - Departments of Radiation Oncology, Medical Biophysics, Medical Oncology, Laboratory Medicine and Pathology and Biostatistics, University of Toronto, Canada
Andrew EVANS - Departments of Radiation Oncology, Medical Biophysics, Medical Oncology, Laboratory Medicine and Pathology and Biostatistics, University of Toronto, Canada
Michael MILOSEVIC - Departments of Radiation Oncology, Medical Biophysics, Medical Oncology, Laboratory Medicine and Pathology and Biostatistics, University of Toronto, Canada
Fred SAAD - Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada
Colin COLLINS - Laboratory for Advanced Genome Analysis - Vancouver Prostate Centre, Vancouver, British Columbia, Canada
Jeremy SQUIRE - Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
Wan LAM - Department of Cancer Genetics and Developmental Biology, British Columbia Cancer Research Centre, Canada
Tarek A BISMAR - Department of Pathology and Laboratory Medicine and Oncology, University of Calgary, Calgary, Alberta, Canada
Paul C BOUTROS - Departments of Radiation Oncology, Medical Biophysics, Medical Oncology, Laboratory Medicine and Pathology and Biostatistics, University of Toronto, Canada
Robert G BRISTOW - Departments of Radiation Oncology, Medical Biophysics, Medical Oncology, Laboratory Medicine and Pathology and Biostatistics, University of Toronto, Canada
Jenna SYKES - Departments of Radiation Oncology, Medical Biophysics, Medical Oncology, Laboratory Medicine and Pathology and Biostatistics, University of Toronto, Canada
Fiona WARDE - Departments of Radiation Oncology, Medical Biophysics, Medical Oncology, Laboratory Medicine and Pathology and Biostatistics, University of Toronto, Canada
Adrian ISHKANIAN - Departments of Radiation Oncology, Medical Biophysics, Medical Oncology, Laboratory Medicine and Pathology and Biostatistics, University of Toronto, Canada
Alice MENG - Departments of Radiation Oncology, Medical Biophysics, Medical Oncology, Laboratory Medicine and Pathology and Biostatistics, University of Toronto, Canada
Chad MALOFF - Department of Cancer Genetics and Developmental Biology, British Columbia Cancer Research Centre, Canada
John SRIGLEY - Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
Anthony M JOSHUA - Departments of Radiation Oncology, Medical Biophysics, Medical Oncology, Laboratory Medicine and Pathology and Biostatistics, University of Toronto, Canada
Gyorgy PETROVICS - Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Rockville, Maryland, United States
Publication Details: Clinical cancer research, Vol.19(18), pp.5202-5209
Publisher: American Association for Cancer Research
Academic Unit: Miller School of Medicine; UMMG Dept of Radiation Oncology
Language: English
Resource Type: Journal article
PMID: 23918607
Record Identifier: 991031600047002976